Why the study?
Is oral and low dose intravenous prostaglandin E2 effective and safe for the management of ductus dependent congenital heart disease in infants?
Population
62 infants and neonates with ductus dependent congenital heart disease
Design
Case_series
Follow-up
mean 49 days (range 16 hours to 272 days)
Authors
Loading...
May support oral PGE2 as bridge to surgery in duct-dependent CHD; leaves open need for prospective trials to confirm safety.
Is oral and low dose intravenous prostaglandin E2 effective and safe for the management of ductus dependent congenital heart disease in infants?
Oral and low-dose intravenous prostaglandin E2 is an effective and well-tolerated strategy for maintaining ductal patency in infants with ductus dependent congenital heart disease prior to surgery.
Silove et al. (1985) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: